Mylan Laboratories Limited – FDA 483, Feb 7, 2020
An FDA inspection of Mylan Laboratories Limited in Sinnar, India, revealed significant deficiencies in their quality control unit, including failures to investigate product-impacting alarms and trend defects. The firm also failed to thoroughly investigate unexplained discrepancies and batch failures, leading to the release of out-of-specification products. Furthermore, a repeat observation highlighted inadequate training and qualification for visual inspectors, raising concerns about product quality assurance.
ID · ddc8b37b-414f-413c-9639-04f25dcb98e6
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.